Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?

Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today? Purpose of ReviewAs outcomes for patients with early-stage breast cancer have improved, oncologists have sought to de-escalate systemic therapy to minimize toxicities while maintaining robust clinical outcomes. This review summarizes current strategies to de-escalate systemic therapy in early-stage breast cancer.Recent FindingsDe-escalation has emerged as an option for some patients with early-stage breast cancer. Recent studies in HERAbstract_Para2-positive breast cancer support de-escalating neoadjuvant regimens with paclitaxel and dual HER2 blockage with additional therapy based on response to chemotherapy. In ER-positive breast cancer, the routine use of genomic testing has identified patients who can be treated with endocrine therapy alone. De-escalation clinical trials in triple-negative breast cancer are sparse; however, prognostic biomarkers may allow de-escalation in select patients.SummaryDe-escalation trials are working toward a tailored personalized medicine approach by selecting the best therapy for each patient focused on optimized clinical outcomes and quality of life. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/right-sizing-systemic-therapy-for-patients-with-breast-cancer-where-iHrhlaKaeX

References (78)

Publisher
Springer Journals
Copyright
Copyright © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-022-00463-1
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewAs outcomes for patients with early-stage breast cancer have improved, oncologists have sought to de-escalate systemic therapy to minimize toxicities while maintaining robust clinical outcomes. This review summarizes current strategies to de-escalate systemic therapy in early-stage breast cancer.Recent FindingsDe-escalation has emerged as an option for some patients with early-stage breast cancer. Recent studies in HERAbstract_Para2-positive breast cancer support de-escalating neoadjuvant regimens with paclitaxel and dual HER2 blockage with additional therapy based on response to chemotherapy. In ER-positive breast cancer, the routine use of genomic testing has identified patients who can be treated with endocrine therapy alone. De-escalation clinical trials in triple-negative breast cancer are sparse; however, prognostic biomarkers may allow de-escalation in select patients.SummaryDe-escalation trials are working toward a tailored personalized medicine approach by selecting the best therapy for each patient focused on optimized clinical outcomes and quality of life.

Journal

Current Breast Cancer Reports – Springer Journals

Published: Dec 1, 2022

Keywords: Systemic chemotherapy, De-escalation; HER2-positive; ER-positive; Triple-negative; Breast cancer

There are no references for this article.